All these guidelines conclude that strategies for managing patients with a retinal disease during this uncertain time should focus on minimizing the risk of exposure to COVID-19 for both patients and healthcare staff, prioritizing treatment for those at greatest risk of irreversible vision loss, and simplifying anti-VEGF treatment regimens [26-27]. This evidence concerns the gene VEGFA and Abnormal retinal morphology.